Indirect Costs in Economic Studies: Confronting the Confusion

PharmacoEconomics

Volumn 4, Issue 6, 1993, Pages 446-454

  Koopmanschap, Marc A ^a   Rutten, Frans F H ^a  

^a ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ABSENTEEISM; ARTICLE; COST OF ILLNESS; HEALTH CARE POLICY; HUMAN; PRODUCTIVITY; SOCIOECONOMICS;

ABSENTEEISM; COST OF ILLNESS; EFFICIENCY; EVALUATION STUDIES; HEALTH POLICY; HUMAN; VALUE OF LIFE;

EID: 0027870525     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.2165/00019053-199304060-00006     Document Type: Review

References (71)

1. Terminal care costs in childhood cancer
2. Impact of the use of absorbable fracture fixation implants on consumption of hospital resources and economic costs
3. Individual correlates of health service utilization and the cost of poor adjustment to chronic illness
4. Economic costs of obesity
5. Economic impact of total hip arthroplasty
6. HRT: an analysis of benefits, risks and costs
7. Epidemiology and social costs of low back pain and fibromyalgia
8. Controlled ovarian hyperstimulation and intrauterine insemination for treatment of infertility
9. Health costs of occupational disease in New York State
10. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive mantoux skin test
11. An overview of the incidences and costs of low back pain
12. The cost of diabetes
13. The mortality, morbidity and economic costs of alcohol abuse in New Hampshire
14. The morbidity, mortality, and economic costs of cigarette smoking in New Hampshire
15. 2-reccptor antagonists in patients with dyspepsia and heartburn: a cost comparison
16. Epidemiology and cost implications of antihypertensive treatment for the prevention of cardiovascular disease
17. Childhood injuries in the United States: mortality, morbidity, and cost
18. The economic impact of injuries: a major source of medical costs
19. A cost-effectiveness analysis of exercise as a health promotion activity
20. Heart disease, cancer and stroke in Maryland
21. The economic costs of Alzheimer’s disease
22. The economic cost of senile dementia in the United States, 1985
23. Economic assessment of peptic ulcer disease treatments
24. The effects of cimetidine on the cost of ulcer disease in Sweden
25. Cost-effectiveness of misoprostol in Sweden
26. Cost-benefit analysis of hepatitis-B vaccination: a computerized decision model for Spain
27. Locomotion status and costs in destructive rheumatoid arthritis: a comprehensive study of 82 patients from a population of 13000
28. Economic impact of type II diabetes mellitus
29. The cost-effectiveness of routine post myocardial infarction exercise stress testing
30. Randomized controlled study of a retiree health promotion program
31. Considerations for a national heart attack alert program
32. Cost-effectiveness of thrombolysis — a randomized study of intravenous rt-PA in suspected myocardial infarction
33. A question of value: measuring the impact of chronic disease
34. Acute hospital costs of trauma in the United States: implications for regionalized systems of care
35. The cost of asthma in New South Wales
36. Assessment of a school exclusion policy during a chickenpox outbreak
37. Costs of temporary and permanent disability induced by diabetes
38. Economic consequences of postinfarction prophylaxis with -blockers: cost effectiveness of metoprolol
39. Cost-benefit analysis of interferon Alfa-2b in treatment of hairy cell leukemia
40. Cost-benefit analysis of an educational program for general practitioners by the Swedish Committee for the prevention and treatment of depression
41. Benefits of a back care and light duty health promotion program in a hospital setting
42. Reducing the costs of patient transfers
43. Estimates of the direct and indirect costs of acquired immunodeficiency syndrome in the United States. 1985, 1986, and 1991
44. The impact of otitis media
45. Chlamydia trachomatis infections in the United States: what arc they costing us?
46. Cost of and payment source for pelvic inflammatory disease
47. An economic evaluation of asthma in the United States
48. The cost of cancer in Texas
49. The normative economics of health care finance and provision
50. Guidelines for economic analysis of pharmaceutical products: a draft document for Ontario and Canada
51. Australian guidelines for cost-effectiveness studies of pharmaceuticals: the thin end of the boomerang?
52. Cost-of-illness studies: a major headache?
53. A cost-effectiveness analysis of the routine use of isoniazid prophylaxis in patients with a positive mantoux skin test
54. The cost of diabetes
55. The Australian guidelines for subsidisation of pharmaceuticals
56. Cost-benefit analysis of hepatitis-B vaccination: a computerized decision model for Spain
57. Towards a new approach for estimating indirect costs of disease
58. Cost-effectiveness of thrombolysis — a randomized study of intravenous rt-PA in suspected myocardial infarction
59. Healthcare resource and lost labour costs of migraine headache in the US
60. Cyclical variation in vacancy durations and vacancy flows, an empirical analysis
61. Cost of illness studies: an aid to decision-making?
62. Economics of coronary artery bypass grafting